Bank of New York Mellon
DMTX

Bank of New York Mellon’s Dimension Therapeutics, Inc DMTX Stock Holding History

Bank of New York Mellon’s Portfolio DMTX Stock Details DMTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-39,626
Closed -$70K – 4455
2017
Q1 		$70K Sell
39,626
-11,265
-22% -$29.9K ﹤0.01% 4096
2016
Q4 		$222K Buy
50,891
+16,457
+48% +$87.6K ﹤0.01% 3870
2016
Q3 		$275K Buy
34,434
+5,691
+20% +$41.1K ﹤0.01% 3793
2016
Q2 		$173K Buy
28,743
+18,506
+181% +$141K ﹤0.01% 3939
2016
Q1 		$80K Buy
+10,237
New +$80.6K ﹤0.01% 4009

Other funds holding DMTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WMSA
Weiss Multi-Strategy Advisers New York $4.16B AUM 30.77% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Bank of New York Mellon's DMTX Position: Q2 2017 in Review

Bank of New York Mellon sold out of Dimension Therapeutics, Inc (DMTX) in Q2 2017, closing a stake of 39,626 shares — an estimated $70K sold.

Bank of New York Mellon first reported a position in DMTX in Q1 2016 and held it in 5 quarters. The position peaked at $275K in Q3 2016. 35 funds tracked by Wall St. Rank hold DMTX as of Q2 2017.

  • Bank of New York Mellon reported no remaining Dimension Therapeutics, Inc position as of Q2 2017 after selling out during the quarter.
  • Bank of New York Mellon sold 39,626 Dimension Therapeutics, Inc shares in Q2 2017, an estimated $70K.
  • Bank of New York Mellon first reported a position in Dimension Therapeutics, Inc in Q1 2016 and held it in 5 quarters.
  • Bank of New York Mellon's Dimension Therapeutics, Inc position peaked at $275K in Q3 2016.
  • 35 funds tracked by Wall St. Rank held Dimension Therapeutics, Inc as of Q2 2017.

Based on Bank of New York Mellon's 13F filing for Q2 2017, filed 3 Aug 2017.